Trends and Disparities in CAR-T Therapy Utilization, Inpatient Mortality, Length of Stay, and Costs in the United States (2017-2022).
Documentation of expanding CAR-T cell therapy access alongside persistent racial and geographic disparities highlights where health systems need to improve equity in this life-saving treatment.
Using US national inpatient data, this study documents growing CAR-T utilization alongside persistent disparities by race, income, and geography from 2017-2022. These real-world access and equity findings are critical for understanding the translational gap between CAR-T trial efficacy and population-level outcomes.
What the study was
- Study design
- Retrospective observational study (US inpatient database, NIS)
- Population
- US adult patients receiving CAR-T cell therapy, 2017-2022
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Transplantation and Cellular Therapy
Why it surfaced
National real-world database study of CAR-T disparities is directly actionable for health equity framing; complements efficacy data with access data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.